AG
YMAB

Aperio Group’s Y-mAbs Therapeutics YMAB Stock Holding History

Aperio Group’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$281K Buy
5,685
+464
+9% +$21.5K ﹤0.01% 2208
2020
Q3 		$200K Buy
5,221
+207
+4% +$8.24K ﹤0.01% 2234
2020
Q2 		$217K Buy
+5,014
New +$190K ﹤0.01% 2153

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Aperio Group's YMAB Position: Q4 2020 in Review

Aperio Group increased its Y-mAbs Therapeutics (YMAB) stake by 8.9% in Q4 2020, buying an estimated $21.5K and bringing the position to 5,685 shares worth $281K. The position accounts for ﹤0.01% of the portfolio, ranked #2208.

Aperio Group first reported a position in YMAB in Q2 2020 and has held it in 3 quarters since. 114 funds tracked by Wall St. Rank hold YMAB as of Q4 2020.

  • Aperio Group held 5,685 shares of Y-mAbs Therapeutics worth $281K as of Q4 2020.
  • Aperio Group bought 464 Y-mAbs Therapeutics shares in Q4 2020, an estimated $21.5K.
  • Y-mAbs Therapeutics made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2208 holding.
  • Aperio Group first reported a position in Y-mAbs Therapeutics in Q2 2020 and has held it in 3 quarters since.
  • 114 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.